PRILOSEC Drug Patent Profile

When do Prilosec patents expire, and what generic alternatives are available?

Prilosec is a drug marketed by Astrazeneca and Azurity and is included in three NDAs.

The generic ingredient in PRILOSEC is omeprazole magnesium. There are two drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the omeprazole magnesium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prilosec

A generic version of PRILOSEC was approved as omeprazole magnesium by DR REDDYS LABS LTD on June 5^th, 2009.

Summary for PRILOSEC

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	144
Clinical Trials:	51
Patent Applications:	4,660
Drug Prices:	Drug price information for PRILOSEC
Drug Sales Revenues:	Drug sales revenues for PRILOSEC
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PRILOSEC
What excipients (inactive ingredients) are in PRILOSEC?	PRILOSEC excipients list
DailyMed Link:	PRILOSEC at DailyMed

See drug prices for PRILOSEC

See drug sales revenues for PRILOSEC

Recent Clinical Trials for PRILOSEC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
Carlos Roberto Simons-Linares	Phase 4
Emory University	Phase 4

See all PRILOSEC clinical trials

Pharmacology for PRILOSEC

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

US Patents and Regulatory Information for PRILOSEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-003	Oct 5, 1995		DISCN	Yes	No
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-001	Mar 20, 2008		RX	Yes	No
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-001	Sep 14, 1989		DISCN	Yes	No
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-002	Jan 15, 1998		DISCN	Yes	No
Astrazeneca	PRILOSEC OTC	omeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	021229-001	Jun 20, 2003		OTC	Yes	Yes
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-002	Mar 20, 2008		RX	Yes	Yes

Expired US Patents for PRILOSEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-002	Mar 20, 2008
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-001	Mar 20, 2008
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-002	Mar 20, 2008
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-001	Mar 20, 2008
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-001	Mar 20, 2008
Azurity	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-002	Mar 20, 2008

International Patents for PRILOSEC

See the table below for patents covering PRILOSEC around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	374471
Austria	374472
Austria	374473
Austria	375365
Austria	389995
Austria	406119
Austria	A100583

Supplementary Protection Certificates for PRILOSEC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0005129	SPC/GB99/015	United Kingdom		SPC/GB99/015, EXPIRES: 20021115
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214

PRILOSEC (omeprazole) market dynamics and financial trajectory: pricing, volume drivers, channel shifts, and key exclusivity/IP milestones

Last updated: July 22, 2026

Prilosec (omeprazole, AstraZeneca) is a mature, off-patent branded proton pump inhibitor (PPI) with broad generic penetration in the U.S. The revenue profile is dominated by (1) generic substitution after loss of brand exclusivity, (2) defensive share retention through pharmacy channel contracts and pack-size/strength mix, and (3) mix shifts tied to chronic GERD and ulcer care patterns. The brand’s financial trajectory has generally tracked category-level PPI demand growth that is partially offset by ongoing price compression and substitution.

What patents protect PRILOSEC (omeprazole) and when does branded exclusivity end?

Prilosec launched as a branded PPI. In the U.S., the actionable market question is not whether omeprazole is “patented,” but when AstraZeneca’s last enforceable claims on the brand product and related line extensions expired, enabling generic entry. With full generic availability, branded pricing power collapses and financial performance becomes dependent on managed-care contracting, specialty/over-the-counter migration, and residual prescribing inertia.

How long did Prilosec keep exclusivity in the U.S.?

Prilosec is widely treated as off-exclusivity and commoditized in the U.S. market for oral omeprazole. Once ANDA generics launched and gained formulary access, the brand moved from a protected launch phase to a declining revenue phase driven by price erosion and channel-level switching.

What patent types historically affect omeprazole brands?

For PPIs like omeprazole, the typical patent buckets include:

• Composition and salts (active ingredient protection)
• Formulation (enteric-coated tablets, stability, excipient systems)
• Methods of use (GERD indications, healing of erosive esophagitis, maintenance therapy)
• Manufacturing/process claims
• Line extensions (dose strengths, delayed-release performance characteristics)

What does that mean for market dynamics?

When composition and formulation protections fall, the remaining value of the brand shifts to:

• Customer retention via rebate strategies and preferred pharmacy status
• Pack and strength mix (what remains differentiated after generics)
• Compliance positioning (brand familiarity and prescriber habit)
• OTC-to-prescription conversion patterns, where applicable

When does Prilosec lose exclusivity, and what generic entry risks exist for omeprazole?

For most market participants, the practical generic risk is “already realized.” The competitive landscape in oral omeprazole is characterized by multiple ANDA products and persistent price competition.

What are the main forces behind generic substitution in Prilosec?

• Bioequivalence-based substitution at the pharmacy counter
• Formulary placement of low-cost generics
• Automatic generic switching policies and pharmacy benefit manager (PBM) tactics
• Payer step edits that encourage lower-cost PPIs

What generic entry barriers still matter?

Even with generic entry, barriers can persist through:

• Contracting and rebate structures that keep brands on formularies (briefly or regionally)
• Patent thickets around specific dosage forms or line extensions (when still active)
• Risk-based incentives in pharmacy contracts that can slow switching

For Prilosec, these barriers have historically been secondary to the broader commoditization of oral omeprazole.

What is the Orange Book status of PRILOSEC (omeprazole) and how many patents are listed?

Orange Book status matters because it indicates the formal patent landscape tied to drug applications. For a commoditized molecule like omeprazole, the Orange Book is usually less predictive of near-term financial upside than it is of litigation calendar risk.

Why Orange Book listings rarely translate into brand revenue in mature PPIs

• Once generics are launched widely, brand revenue depends on contracting, not exclusivity
• Even if patents remain listed, the market often prices in expected generic availability
• Brand margins shrink as net prices fall and volume migrates to generics

How does Prilosec perform financially after generic erosion?

Prilosec’s financial trajectory is best understood as a post-exclusivity decline with periodic volatility tied to:

• OTC penetration and seasonality in GERD self-management
• Channel inventory cycles and PBM formulary moves
• Competitor PPI mix shifts (esomeprazole, lansoprazole, pantoprazole)
• Supply disruptions and pack-size discontinuations in the broader category

What “financial trajectory” usually looks like for mature PPIs

• Launch years: higher net price, protected share, strong top-line growth
• Mid-life: plateau as generics appear; net price starts to compress
• Mature phase: sustained volume share pressure; residual brand sales become contract-driven
• Long tail: revenue becomes mix-of-strength and channel-contract dependent

For Prilosec, the sustained generic presence typically caps upside and locks the brand into a declining, defense-only strategy.

What market dynamics drive demand for omeprazole and PPIs in the U.S.?

Demand for PPIs is driven by diagnosis prevalence and treatment persistence in:

• GERD
• Peptic ulcer disease
• Maintenance of erosive esophagitis
• Off-label or protocol-driven uses in GI prophylaxis settings (where payer coverage supports)

What shifts move the market?

• Clinical guideline updates that affect step therapy and initial selection
• Increased generic utilization through PBM formularies
• Increased OTC availability for certain regimens that can reduce prescription volumes
• Longer-term safety discussions that can shift prescriber behavior across PPIs (often among generics rather than away from the class)

How do competitive PPIs affect Prilosec share?

Even within a generic molecule category, competition occurs across PPIs:

• Esomeprazole (Nexium brand and generics)
• Lansoprazole (Prevacid brand and generics)
• Pantoprazole (Protonix brand and generics)

In mature markets, brand survival is usually about rebate-driven share retention, not therapeutic differentiation.

What pricing and rebate dynamics determine Prilosec net revenue?

For off-patent PPIs, gross-to-net mechanics dominate. The brand’s financials are influenced by:

• PBM rebate rates and payer-specific contract terms
• Pharmacy channel inventory pricing, chargeback rates, and reimbursement caps
• Publicized price erosion versus actual net price (rebates can mask nominal list reductions)

How does price compression typically propagate?

• Once generic equivalents are widely stocked, pharmacy reimbursement benchmark pricing shifts
• Wholesale and retail pricing pressure increases, net prices fall for the brand
• Brand volume becomes concentrated in patients not immediately switching (new-to-therapy inertia, formulary exceptions)

How does Prilosec compare with Nexium, Prevacid, and Protonix on market positioning?

At a high level:

• All are PPIs with broad generic availability in the U.S.
• Their residual branded positioning depends on historical brand equity, contraction of net price, and defensive contracting.

For a brand like Prilosec, the competitive question is less “which PPI is clinically superior” and more:

• Which brand retains a higher net share under PBM and insurer agreements?
• Which has stronger pack-size, strength, or channel coverage for managed-care scripts?

What litigation or settlements affected PRILOSEC competitive entry?

In commoditized actives like omeprazole, litigation impacts are typically historical and tied to ANDA launch timing. The economic relevance is measured by:

• Whether a settlement delayed generic entry in a particular timeframe
• Whether it limited specific product formulations or labeling designs

For the current market structure, the key point is that the generic ecosystem is already established. Any remaining litigation effects are usually about incremental product variants rather than ending a threat entirely.

What is the biosimilar or biologics angle for PRILOSEC?

None. Prilosec is a small-molecule PPI, not a biologic. The competitive replacement mechanisms are ANDA generics and branded-to-generic substitution, not biosimilars.

What formulations of omeprazole matter commercially?

Commercially relevant formulation attributes include:

• Delayed-release enteric coating for acid stability
• Strength and pack configuration (OTC vs prescription formats)
• Switching considerations tied to dissolution and patient tolerance

As generics normalize formulation approaches, differentiation narrows to packaging, labeling, and contract-driven access.

What generic launch scenarios could still affect PRILOSEC revenue?

With the molecule already commoditized, remaining launch “scenarios” are usually:

• Competitive price resets driven by new ANDAs or additional manufacturers
• Shifts in contract tiers (preferred generic tiers that move patients away from higher-cost generics to lower-cost options)
• Repackaging changes that affect pharmacy supply and substitution behavior

The market impact is mostly downward on brand net price rather than a full reversal of generic penetration.

Geographic considerations: where does Prilosec face the most competition?

The fiercest competitive pressure is typically in:

• U.S. managed-care channels with aggressive generic placement and PBM switching
• Retail pharmacy channels with automatic generic substitution
• Countries where omeprazole is off patent and multiple suppliers exist

In less saturated markets, branded entities can retain higher nominal pricing longer through slower reimbursement policy switching. In the U.S., the trajectory is structurally pressured.

Key takeaways

• Prilosec (omeprazole) is a mature, off-exclusivity PPI in a market dominated by generic substitution and price compression.
• The brand’s financial trajectory is largely driven by gross-to-net pricing, PBM contracting, and channel mix, not new exclusivity.
• Remaining competitive sensitivity comes from formulary contract shifts, pack-size/strength mix, and incremental competitor pricing rather than fundamental supply barriers.
• Comparisons across PPIs (Nexium, Prevacid, Protonix) show class-level demand stability but brand-level erosion through the same generic dynamics.

FAQs

1) Does Prilosec compete mainly on prescription formulary placement or OTC traffic?
It competes on both, but U.S. net revenue outcomes are highly dependent on PBM and payer formulary tiers plus residual prescription retention after generic penetration.

2) How do PPIs like omeprazole typically lose share to other PPIs?
Share shifts through payer preferred-list policies, step therapy rules, and patient persistence patterns, often moving between generics or between branded products with contract-driven positioning.

3) What metrics best track Prilosec market health in a generic-dominated environment?
Gross-to-net net price, unit share by strength/pack, and managed-care tier status drive the story more than list price.

4) Can litigation still protect Prilosec-like brands after generic launch?
Litigation can affect narrow product variants or timing, but for off-patent molecules with broad ANDA coverage, long-term revenue is typically governed by contracting and substitution.

5) Is Prilosec still relevant for long-term GERD management?
Yes, class-level demand remains steady given chronic use patterns, though patient and prescriber behavior increasingly defaults to the lowest-cost reimbursed option.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA (Orange Book).

DrugChatter Q&A for PRILOSEC

What is the difference between prilosec and nexium?